List of Regenerative Medicine Companies in South Korea - 12

bBHC Stem Cell Treatment & Research Institute discovered the newly Elicited pluripotent Stem Cell without side effects which is called nEPS. We've been differentiated nEPS into endoderm,mesoderm and ectoderm. Our goal is overcome to incurable diseas using in nEPS.

Founded in 2019, Brexogen is at the forefront of biotechnological innovation, dedicated to transforming the treatment of incurable diseases through our proprietary BG-Platform technology. As a pioneering bioventure, we specialize in the development of cell-free therapies, leveraging the untapped potential of stem cell derived exosomes. Our mission intertwines groundbreaking research with practical healthcare solutions. As we gear up for global expansion, our strategy emphasizes understanding local markets, forging strategic partnerships, continuous innovation, and engaging with the medical community to promote the benefits of exosome therapy. Rooted in South Korea, Brexogen is on a trajectory to enhance healthcare outcomes worldwide. We're dedicated to leading the charge in biotechnological innovation, offering accessible, effective treatments on a global scale. Join our journey as we strive for a healthier future across communities globally.

Cellatose Therapeutics Co., Ltd. is a company specializing in cell therapy development that was established in August 2017 with the goal of ‘ resolving unmet needs for incurable diseases . ’ The nation's best cell therapy research and development experts are gathering to discover differentiated cell and platform technologies and promote the commercialization of cell therapy products.

CHA Biotech is the only company in Korea that has a collective eco-system integrating CHA Medical University, CHA Advanced Research Institute, and CHA Hospitals within the group collaborating to develop new drugs by conducting basic research and clinical trials up to commercialization. CHA Biotech has the world's largest cell library (embryonic and adult stem cells, immune cells) that can be applied to cure various diseases, and has differentiated technology including 88 globally registered patents for cell technology. Based on our R&D competency, the company develops cell and gene therapies for diseases that are unmet and are in high demand for cure such as cancer, incurable diseases, and aging-related diseases.

Curamys is a biotechnology company that develops cell fusion technology to cure intractable diseases.

Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals for previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease and Charcot-Marie-Tooth disease. Helixmith clinical development activities are based in San Diego, California,

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies.

JW Pharmaceutical Corp. (formerly Choongwae Pharma) is one of the leading pharmaceutical companies in Korea with core competencies in antibiotics, IV solutions, and anti-cancer treatments. JW is currently exploring targeted therapies in oncology leveraging the collaborative research and development strengths from the JW Drug Discovery Center in Korea and the JW Theriac Corp in the US. This R&D pipeline is driven by our platform technologies that have the potential to eradicate cancer stem cells selectively through a molecularly targeted approach. ------- JW Group consists of JW Holdings, JW Pharmaceutical, JW Medical, JW ShinYak, JW Industrial, JW Life Science, and JW Creagene. JW possesses i) magnificent sales force (900 reps) for the hospital market, ii) strong relationships with managements of hospitals & and hospital pharmacies, iii) excellent rapport with key opinion leaders in endocrinology, gastroenterology, oncology, cardiology, nephrology, urology and the general surgery therapeutic areas. JW's total sales revenue of US $ 0.7 billion was derived from Korea and other several Asian countries in 2012

MEDIPOST is founded in 2000, and today MEDIPOST is leading the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012. MEDIPOST operates the largest private cord blood bank “CELLTREE®” in Korea with over 255,000 units of private cord blood units under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD). MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit)” PNEUMOSTEM® (allogeneic Umbilical Cord Blood-derived MSCs) for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants, completed the first-in-human Phase I safety trial in Korea and the randomized, placebo-controlled Phase II clinical trial is ongoing in Korea. Phase I/II clinical trial in the U.S. has been completed confirming safety with positive efficacy signals. MEDIPOST’s 2nd generation human Umbilical Cord Blood-derived Mesenchymal Stromal Cell (hUCB-MSC) pipeline code named SMUP-IA-01 is an off-the-shelf intra-articular injectable cell product for the patients with early to mid-stage knee osteoarthritis (OA).

[About ROKIT Healthcare] ROKIT Healthcare is a First Mover in regenerative healthcare, pioneering innovations that reduce medical costs for governments and patients while driving healthcare transformation. Our mission is to extend healthy lifespans and enhance quality of life through cutting-edge technologies. At the heart of our vision lies the AI Hyper-Personalized Organ Regeneration Platform, a revolutionary solution designed to meet critical medical needs and redefine the future of medicine. [What We Do] - AI-Driven Organ Regeneration: Combining advanced bioprinting and AI to deliver hyper-personalized therapies for organ and tissue regeneration. - Anti-aging Bio-suppliment Products: Leading the anti-aging market with NMN, offering scientifically proven and effective solutions for better health. (ROKIT America) - Genomics: Utilizing AI-powered single-cell RNA-seq analysis to develop innovative diagnostics and precision medicine. (ROKIT Genomics) [Why ROKIT Healthcare?] We are committed to creating a sustainable and innovative healthcare ecosystem that benefits governments, healthcare providers, and patients. By addressing the root causes of medical challenges and reducing costs, we aim to make advanced healthcare accessible to all. [ROKIT Healthcare에 대하여] - ROKIT Healthcare는 재생 의료 분야의 First Mover로서, 정부와 환자의 의료비를 절감하고 의료 혁신을 주도하는 기술과 아이디어를 선도하고 있습니다. -우리의 사명은 최첨단 기술을 통해 건강 수명을 연장하고 삶의 질을 향상시키는 것입니다. 이러한 비전의 핵심에는 AI Hyper-Personalized Organ Regeneration Platform이 자리 잡고 있으며, 이는 의료의 중요한 과제를 해결하고 미래 의료의 패러다임을 재정의하는 혁신적인 솔루션입니다. [우리가 하는 일] - AI 기반 장기 재생: 첨단 바이오프린팅과 AI를 결합하여 개개인 맞춤형 장기 및 조직 재생 치료를 제공합니다. - 항노화 바이오 보충제 제품: 과학적으로 검증된 NMN으로 항노화 시장을 선도하며 건강을 위한 효과적인 솔루션을 제공합니다. (ROKIT America) - 유전체학: AI 기반 단일 세포 RNA-seq 분석을 활용하여 혁신적인 진단 및 정밀 의학 솔루션을 개발합니다. (ROKIT Genomics) [ROKIT Healthcare가 특별한 이유] 우리는 정부, 의료 제공자, 그리고 환자 모두에게 혜택을 주는 지속 가능하고 혁신적인 의료 생태계를 만들기 위해 노력하고 있습니다. 의료 문제의 근본적인 원인을 해결하고 비용을 절감함으로써, 선진 의료 기술을 모두가 접근 가능하게 만드는 것을 목표로 하고 있습니다.

At Xcell Therapeutics, we believe that scientists and researchers should have the opportunity to develop groundbreaking treatments to cure disease, ensure good health, and limit animal suffering in research. That's why we have develop and produce serum-free, chemically defined media that provides for better research results and greater consistency in manufacturing. Our media is carefully designed and manufactured with precision to help our customers in bioengineering and life sciences achieve a better future for humanity.